摘要
免疫检查点抑制剂应用于肿瘤免疫治疗的同时可引起免疫相关不良事件,其中不良反应为糖尿病的较为少见。本文报道1例由免疫检查点抑制剂信迪利单抗治疗肺癌患者引发糖尿病合并糖尿病酮症酸中毒的诊治经过,并进行相关文献复习。
Immune checkpoint inhibitors can cause immune-related adverse events when they are used in tumor immunotherapy,but the cases of diabetes mellitus are rare.This article reported a case of diabetes mellitus complicated with ketoacidosis caused by the treatment of lung cancer patients with immune checkpoint inhibitor Sindilimab and related literature review.
作者
华纯山
李中川
刘学威
HUA Chunshan;LI Zhongchuan;LIU Xuewei(Weishan County People’s Hospital,Endocrinology Department,Jining 277600 Shandong,China;Weishan County People’s Hospital,Intensive Care Unit,Jining 277600 Shandong,China)
出处
《中国民康医学》
2024年第19期140-142,共3页
Medical Journal of Chinese People’s Health
关键词
信迪利单抗
糖尿病
酮症酸中毒
Sintilimab
Immune checkpoint inhibitor
Diabetes mellitus